Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug, Pepaxti, is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere. Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE. The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO. For more information, visit: www.oncopeptides.com
Looking for a particular Oncopeptides AB employee's phone or email?
Oncopeptides AB Questions
The Oncopeptides AB annual revenue was $11.7 million in 2026.
Eva Nordström is the COO of Oncopeptides AB.
64 people are employed at Oncopeptides AB.
The NAICS codes for Oncopeptides AB are [3254, 32541, 32, 325].
The SIC codes for Oncopeptides AB are [28, 283].
Top Oncopeptides AB Employees
-
Eva Nordström
Chief Operating Officer at Oncopeptides AB
Stockholm, SE2 -
Henrik Bergentoft
Chief Financial Officer at Oncopeptides AB
Stockholm County, Sweden2 -
Stefan Norin
Chief Medical Officer at Oncopeptides AB
Stockholm, SE3 -
35+
-
Stefan Gelius
Head of Research at Oncopeptides AB
Stockholm, SE2 -
2
-
25+
-
Lina Rydner
Head of CMC at Oncopeptides AB
Stockholm County, Sweden2
Related Companies
